Dr. Crinò on Crizotinib in ALK-Positive NSCLC
Lucio Crinò, MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer